MSB 2.01% $1.46 mesoblast limited

Ann: US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial, page-210

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. wot
    10,310 Posts.
    lightbulb Created with Sketch. 1459
    Problems.

    - pushed by Giuliani and Trump not the Fda
    - not proved safety
    - umbilical killer cells might trigger immune response, exact opposite to quelling the storm. So might end up killing patients
    - no compassionate use granted
    - initial trial 60 days will then need placebo trial after - another 3- 4 months. 6 months, then will need to apply to fda
    - meso milder dose is proving more effective than other treatments

    Conclusion - shot in the dark.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.